Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts.
Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts.
复制标题
根据 KRAS 和 BRAF 突变的维生素 C 摄入量和结直肠癌生存率：一项针对两个美国队列的前瞻性研究。
DOI：
10.1038/s41416-023-02452-2
复制
发表时间：
2023
影响因子：
8.8
通讯作者：
Song,Mingyang
中科院分区：
文献类型：
--
作者：
Shi,Shanshan;Wang,Kai;Ugai,Tomotaka;Giannakis,Marios;Cazaubiel,Jules;Chan,AndrewT;Giovannucci,EdwardL;Nowak,JonathanA;Meyerhardt,JeffreyA;Ogino,Shuji;Song,Mingyang
BackgroundThe associations of vitamin C intake with colorectal cancer（CRC）survival according to tumourKRASorBRAF mutation status.MethodsWe used the inverse probability weighted multiple考克斯proportional hazards regression model to calculate the hazard ratio（HR）of mortality，and spline analysis to evaluate the dose-response relationship in the Nurses' Health Study and Health Professionals Follow-up Study.我们还根据TCGA数据库中的KRA或BRAF突变评估了SLC 2A 1 mRNA表达。结果在平均12.0年的随访期间，我们记录了2,096例CRC病例，其中703例具有KRA和BRAF突变数据。总维生素C摄入量和CRC特异性死亡率之间的关系根据KRA或BRAF突变状态而明显不同。（P相互作用= 0.04），维生素C摄入量每增加400 mg/天，CRC特异性死亡率的多变量HR（95% CI）为1.07（0.87- 1.32，P趋势= 0.52），KRA或BRAF突变型为0.74（0.55- 1.00，P趋势< 0.05）。TCGA分析显示，KRASorBRAF突变肿瘤中mRNASLC 2A 1表达高于野生型肿瘤（P= 0.02）。结论我们的研究结果支持维生素C对KRASorBRAF突变肿瘤CRC患者的潜在益处的实验室证据。
BackgroundThe associations of vitamin C intake with colorectal cancer (CRC) survival according to tumourKRASorBRAFmutation status remain unclear.MethodsWe used the inverse probability weighted multivariable Cox proportional hazards regression model to calculate the hazard ratio (HR) of mortality, and spline analysis to evaluate the dose–response relationship in the Nurses’ Health Study and Health Professionals Follow-up Study. We also assessedSLC2A1mRNA expression according toKRASorBRAFmutation in the TCGA database.ResultsDuring an average of 12.0 years of follow-up, we documented 2,096 CRC cases, of which 703 cases hadKRASandBRAFmutation data. The association between total vitamin C intake and CRC-specific mortality suggestively differed according toKRASorBRAFmutation status (Pinteraction= 0.04), with the multivariable HR (95% CI) per 400 mg/day increase in vitamin C intake for CRC-specific mortality of 1.07 (0.87–1.32,Ptrend= 0.52) in cases with both wild type and 0.74 (0.55–1.00,Ptrend< 0.05) in cases with eitherKRASorBRAFmutant type. TCGA analysis showed a higher mRNASLC2A1expression inKRASorBRAF-mutatedtumours than in wild-type tumours (P= 0.02).ConclusionOur findings support the laboratory evidence for a potential benefit of vitamin C for CRC patients withKRASorBRAFmutated tumours.